Clinical trial · no report yet · Phase 3
MoonRISe-1
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
- NCT06319820 ↗
- Recruiting
- Janssen Research & Development, LLC
- 37 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 16 | |
| Podcasts | 11 | |
| X threads | 10 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non-Muscle Invasive Bladder Neoplasms
- Interventions
- TAR-210; Gemcitabine; MMC
- Arms
- Main Study: Group A: TAR-210 · Experimental
- Main Study: Group B: MMC or Gemcitabine · Active comparator
- Substudy: Group A: TAR-210 · Experimental
- Substudy: Group B: MMC · Active comparator
- Enrollment
- 641 (estimated)
- Primary outcomes
- Disease Free Survival (DFS)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Apr 18, 2024
- Primary completion
- Jun 28, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06319820 · updated Sep 25, 2026